<DOC>
	<DOCNO>NCT00097929</DOCNO>
	<brief_summary>A study determine safety , tolerability , anti-tumor effectiveness oral investigational drug treatment relapse diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>An Investigational Drug Study With Suberoylanilide Hydroxamic Acid Relapsed Diffuse Large B-cell Lymphoma ( 0683-013 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient must 18 year old relapse Diffuse Large Bcell Lymphoma ( DLBCL ) . Stable disease well least 3 month recent treatment Have receive chemotherapy , radiation therapy , major surgery , investigational therapy least 4 week prior entry study Adequate blood testing , liver , kidney function require study . Eligible subject allow tissue sample examine store . Patient treat investigational agent similar antitumor mechanism . Patient fail 3 prior treatment regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Relapsed Diffuse Large B-cell Lymphoma</keyword>
</DOC>